21.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
29.60%
207.28
|
159.93 | 166.50 | 139.29 | 139.49 |
|
|
3.10%
320.56
|
330.82 | 274.38 | 282.23 | 271.48 |
| Benefits Costs and Expenses |
1.33%
334.96
|
339.47 | 280.50 | 289.06 | 272.71 |
| Costs And Expenses |
1.33%
334.96
|
339.47 | 280.50 | 289.06 | 272.71 |
| Operating Income/Loss |
33.71%
-113.28
|
-170.89 | -107.89 | -142.94 | -131.99 |
| Income/Loss From Continuing Operations Before Tax |
28.88%
-127.69
|
-179.54 | -114.00 | -149.77 | -133.21 |
| Income Tax Expense/Benefit |
0.34%
0.87
|
0.873 | 0.947 | 1.31 | 0.303 |
| Income/Loss From Continuing Operations After Tax |
28.74%
-128.56
|
-180.41 | -114.95 | -151.08 | -133.52 |
|
|
28.74%
-128.56
|
-180.41 | -114.95 | -151.08 | -133.52 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
99.59%
0.4136
|
99.77 | 98.46 | 96.29 | 95.49 |
| Diluted Average Shares |
99.59%
0.4136
|
99.77 | 98.46 | 96.29 | 95.49 |
| Basic Earnings Per Share |
29.28%
-1.28
|
-1.81 | -1.17 | -1.57 | -1.40 |
| Diluted Earnings Per Share |
29.28%
-1.28
|
-1.81 | -1.17 | -1.57 | -1.40 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):